Clinical Trial Update: A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 study evaluating RO4602522 in participants with moderate Alzheimer's disease on background therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• RO4602522

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED